AD-9308
Based on 1 Customer Validation
AD-9308 is an orally active, highly selective aldehyde dehydrogenase 2 (ALDH2) activator. AD-9308 alleviates oxidative stress, improves mitochondrial function, restores cell viability, reduces renal tubular injury, fibrosis and inflammatory responses, reverses ventricular remodeling, restores the activities of Dicer and superoxide dismutase, inhibits the IL-6 signaling pathway, reduces the accumulation of 4-HNE-protein adducts, and improves glucose homeostasis. AD-9308 can be used in studies related to acrolein-induced kidney injury, diabetes, cardiomyopathy, heart failure, diet-induced obesity, fatty liver, insulin resistance and glucose intolerance.
For research use only. We do not sell to patients.
- CAS No.: 1804942-56-0
- Formula: C30H36FN3O5
- Molecular Weight:537.62
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
|
ALDH2 |
IL-6 |
In Vitro
AD-9308 activates both wild-type and ALDH2E487K mutant ALDH2 proteins[1].
AD-9308 (100 μM) activates recombinant wild-type human ALDH2 protein via its active metabolite AD-5591, increasing the enzyme activity to approximately 1600 μmol NADH/min/mg protein[5].
AD-9308 alleviates acrolein-induced ferroptosis and mitochondrial dysfunction, and enhances the cell viability of primary mouse proximal tubular epithelial cells with Aldh2-WT and Aldh22/2, via its active metabolite AD-5591 (10 μM; 1 h pre-incubation)[1].
AD-9308 (preincubated for 1 h; incubated for 72 h under high glucose/high palmitic acid conditions) maintains the viability and ATP production of H9c2 cardiomyocytes and inhibits cell apoptosis under high glucose and high palmitic acid conditions[2].
AD-9308 (5-10 μM; 1 h pre-incubation; 72 h incubation under high-glucose/high-palmitate conditions) inhibits NF-κB activation in H9c2 cardiac fibroblasts under high-glucose and high-palmitate conditions by stabilizing IκBα and reducing p65 nuclear translocation[2].
AD-9308 (incubated under high glucose/high palmitate conditions) improves mitochondrial respiratory function of H9c2 cardiomyocytes under high glucose and high palmitate conditions[2].
AD-9308 (5-10 μM; incubation under high-glucose/high-palmitate conditions; 30 min Fura-2-AM loading) restores SR/ER Ca2+ levels in H9c2 cardiomyoblasts exposed to a high-glucose and high-fat environment[2].
AD-9308 (the active form of AD-5591) (20 μM; 16 h) restores ALDH2 activity, alleviates oxidative stress, rescues angiogenic function, restores eNOS activity, and reduces the secretion of pro-inflammatory/pro-proliferative cytokines in human pulmonary artery endothelial cells treated with the ALDH2 inhibitors daidzein and 4-hydroxynonenal[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
AD-9308 (60-180 mg/kg/day; p.o.; daily; ~4 months) dose-dependently improves left ventricular diastolic and systolic function, mitigates cardiac structural remodeling, reduces oxidative stress, fibrosis, inflammation, and apoptosis, and restores mitochondrial function in Streptozotocin (HY-13753)-induced diabetic Mus musculus, with significant linear trends observed across multiple efficacy endpoints[2].
AD-9308 (40 mg/kg/day; oral gavage; twice daily; six weeks) restores Dicer activity, reduces cardiac remodelling, and improves left ventricular ejection fraction in myocardial infarction-induced heart failure in Rattus norvegicus via enhanced ALDH2-mediated 4-HNE clearance[3].
AD-9308 (60 mg/kg; p.o.; daily; 4 weeks) mitigates hypoxia-induced pulmonary hypertension in heterozygous ALDH21/2 knock-in mice by reducing right ventricular systolic pressure, right ventricular hypertrophy, pulmonary arterial remodeling, oxidative stress, 4-HNE-protein adduct accumulation, and endothelial IL-6 association[4].
AD-9308 (20-60 mg/kg/day; p.o.; daily; 20 weeks) dose-dependently attenuates diet-induced obesity, fatty liver, insulin resistance, and glucose intolerance in male C57BL/6J Aldh2 wild-type mice by reducing serum 4-HNE levels[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J Aldh22/2 (Glu504Lys knock-in) (male, 6 weeks old, chronic oral acrolein-induced renal injury)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; daily; 12 consecutive weeks
-
Result:Markedly reduced acrolein-induced increases in urine albumin-to-creatinine ratio (UACR) and blood urea nitrogen (BUN) levels.
Ameliorated acrolein-induced tubular damage including vacuolar degeneration, epithelial swelling, tubular dilation, and interstitial fibrosis.
Reversed acrolein-induced kidney GSH depletion, reduced acrolein-increased renal ferrous iron (Fe2+) accumulation, and lowered elevated renal malondialdehyde (MDA) levels.
Substantially attenuated acrolein-induced increases in renal acrolein-protein conjugates (Acr-PC), neutrophil gelatinase-associated lipocalin (NGAL), fibronectin, and alpha-smooth muscle actin (α-SMA) protein expression.
Reduced acrolein-induced upregulation of mRNA expression for tubular injury markers (NGAL, KIM-1) and pro-inflammatory cytokines (IL-6, TGF-β).
-
Animal Model:C57BL6/J mice (8-week-old at study initiation; streptozotocin-induced hyperglycemia)[2]
-
Dosage:60 mg/kg/day; 180 mg/kg/day
-
Administration:p.o.; daily; ~4 months
-
Result:Improved left ventricular diastolic function with significant linear trends for E/A ratio (p-for-trend = 0.0180), e’ wave velocity (p-for-trend = 0.0002), E/e’ ratio (p-for-trend = 0.0202), e’/a’ ratio (p-for-trend = 0.0019), and isovolumic relaxation time (p-for-trend = 0.0107).
Improved systolic function with significant linear trends for fractional shortening (p-for-trend = 0.0055), ejection fraction (p-for-trend = 0.0042), stroke volume (p-for-trend = 0.0006), cardiac output (p-for-trend = 0.0004), and s wave velocity (p-for-trend = 0.0167).
Mitigated reductions in interventricular septum thickness at end diastole (p-for-trend = 0.0022) and left ventricular mass (p-for-trend = 0.0015).
Reduced serum 4-hydroxy-2-nonenal (4-HNE) levels, cardiac tissue 4-HNE protein adducts, and cardiac heme oxygenase 1 (Ho-1) expression.
Enhanced cardiac ALDH2 enzymatic activity.
Reduced cardiac mRNA expression of fibrosis markers Tgf-β1 (p-for-trend < 0.0001), Ctgf (p-for-trend < 0.0001), Fsp1 (p-for-trend = 0.0026), Postn (p-for-trend = 0.0046), Fn-1 (p-for-trend = 0.0001), and Tgf-β2 (p-for-trend = 0.0004), as well as α-Sma (p-for-trend = 0.0367) and Col IV (p-for-trend = 0.0113) mRNA and protein deposition.
Reduced cardiac mRNA expression of inflammatory markers Il-1β (p-for-trend = 0.0010), Il-6 (p-for-trend = 0.0002), Infγ (p-for-trend = 0.0054), Mcp-1 (p-for-trend = 0.0047), Sap (p-for-trend = 0.0005), and Tnf-α (p-for-trend < 0.0001).
Increased cardiac Bcl-2 expression, reduced iNOS, Bax, and cleaved caspase 3 expression, stabilized IκBα protein, and reduced NF-κB p65 nuclear translocation and activity.
Improved cardiac mitochondrial electron transfer chain complex II and III activities, reversed diabetic shifts in mitochondrial dynamic regulators (reduced Drp1, normalized Opa1 processing), and lowered cardiac autophagy markers Beclin 1 and LC3A/B II expression.
-
Animal Model:Wistar normotensive male rats (12 weeks of age at study initiation; myocardial infarction-induced heart failure model)[3]
-
Dosage:40 mg/kg/day
-
Administration:oral gavage; twice daily; six weeks
-
Result:Restored cardiac Dicer activity to levels comparable to vehicle-treated sham rats.
Reduced left ventricular end-diastolic diameter, cardiomyocyte cross-sectional area, left ventricular fibrosis, and inflammatory cell infiltration compared to vehicle-treated heart failure controls.
Improved left ventricular ejection fraction, re-established cardiac ALDH2 catalytic activity, and reduced cardiac 4-HNE protein adduct levels in heart failure rats.
Showed no significant effects on cardiac morphology, function, aldehyde clearance, or Dicer function in sham-treated rats.
-
Animal Model:heterozygous ALDH2*1/*2 knock-in (male, 10-week-old, chronic 10% O2 hypoxia for 4 weeks induced pulmonary hypertension)[4]
-
Dosage:60 mg/kg
-
Administration:p.o.; daily; 4 weeks
-
Result:Significantly reduced hypoxia-induced increases in right ventricular systolic pressure.
Reduced the Fulton index (right ventricular hypertrophy marker).
Restored lung superoxide dismutase activity.
Decreased the percentage of pulmonary arterial wall thickness.
Lowered the signal intensity of 4-HNE-protein adducts in pulmonary arteries.
Attenuated hypoxia-induced increases in proximity ligation assay signal (indicating reduced interleukin-6 association with pulmonary arterial endothelial cells).
-
Animal Model:C57BL/6J Aldh2 wild-type (male; fed high-fat high-sucrose diet from 10 weeks of age)[5]
-
Dosage:20 mg/kg/day; 60 mg/kg/day
-
Administration:p.o.; daily; 20 weeks
-
Result:Reduced diet-induced weight gain dose-dependently.
Decreased weights of perigonadal fat, inguinal fat, and omental fat.
Reduced adipocyte hypertrophy.
Decreased hepatic steatosis severity and hepatic triglyceride levels.
Lowered fasting glucose levels.
Improved insulin sensitivity and glucose tolerance.
Reduced serum 4-hydroxynonenal (4-HNE) levels.
-
Animal Model:C57BL/6J Aldh2 homozygous knock-in (male; mimicking human Glu504Lys mutation; fed high-fat high-sucrose diet from 10 weeks of age)[5]
-
Dosage:20 mg/kg/day; 60 mg/kg/day
-
Administration:p.o.; daily; 20 weeks
-
Result:Reduced diet-induced weight gain dose-dependently.
Decreased weights of perigonadal fat, inguinal fat, and omental fat.
Reduced adipocyte hypertrophy.
Decreased hepatic steatosis severity and hepatic triglyceride levels.
Lowered fasting glucose levels.
Improved insulin sensitivity and glucose tolerance.
Reduced serum 4-hydroxynonenal (4-HNE) levels.
Reduced the number of 4-HNE-adducted mitochondrial proteins involved in fatty acid oxidation and electron transport chain in brown adipose tissue.
Chemical Information
-
CAS No. 1804942-56-0
-
Appearance Oil
-
Molecular Weight 537.62
-
Formula C30H36FN3O5
-
SMILES
CC(C)[C@H](N)C(OCC1=C(C2=CC(C(NCC3=CC(F)=C(C=C3)OC)=O)=C(C=C2)OCC(C)C)N=CC=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (186.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
References
[1]. Kuo YM, et al. Aldehyde dehydrogenase 2 mitigates acrolein-driven ferroptosis to preserve kidney function. Environmental pollution (Barking, Essex : 1987). 2026 Feb 01;390:127555. [Content Brief]
[2]. Lee HL, et al. A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice. Antioxidants (Basel, Switzerland). 2021 Mar 13;10(3):450. [Content Brief]
[3]. Kiyuna LA, et al. 4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification. European heart journal. 2023 Nov 21;44(44):4696-4712. [Content Brief]
[4]. Chou YH, et al. Deciphering endothelial aldehyde dehydrogenase 2, oxidative stress, and interleukin-6 interactions in pulmonary hypertension: Implications for precision medicine. Biochemical pharmacology. 2026 Jan;243(Pt 1):117510. [Content Brief]
[5]. Chang YC, et al. A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators. Nature communications. 2023 Sep 25;14(1):5971. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8600 mL | 9.3002 mL | 18.6005 mL | 46.5012 mL |
| 5 mM | 0.3720 mL | 1.8600 mL | 3.7201 mL | 9.3002 mL | |
| 10 mM | 0.1860 mL | 0.9300 mL | 1.8600 mL | 4.6501 mL | |
| 15 mM | 0.1240 mL | 0.6200 mL | 1.2400 mL | 3.1001 mL | |
| 20 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL | 2.3251 mL | |
| 25 mM | 0.0744 mL | 0.3720 mL | 0.7440 mL | 1.8600 mL | |
| 30 mM | 0.0620 mL | 0.3100 mL | 0.6200 mL | 1.5500 mL | |
| 40 mM | 0.0465 mL | 0.2325 mL | 0.4650 mL | 1.1625 mL | |
| 50 mM | 0.0372 mL | 0.1860 mL | 0.3720 mL | 0.9300 mL | |
| 60 mM | 0.0310 mL | 0.1550 mL | 0.3100 mL | 0.7750 mL | |
| 80 mM | 0.0233 mL | 0.1163 mL | 0.2325 mL | 0.5813 mL | |
| 100 mM | 0.0186 mL | 0.0930 mL | 0.1860 mL | 0.4650 mL |
Keywords
- AD-9308
- 1804942-56-0
- AD9308
- AD 9308
- Aldehyde Dehydrogenase (ALDH)
- Interleukin Related
- acrolein
- C57BL/6J Aldh2 wild-type mice
- aldehyde dehydrogenase 2
- myocardial infarction-induced heart failure
- H9c2 cardiomyoblasts
- 4-hydroxy-2-nonenal
- human pulmonary arterial endothelial cells
- streptozotocin-induced diabetic mice
- Inhibitor
- inhibitor
- inhibit